PERTH, AUSTRALIA: November 22, 2012 – Phylogica Ltd (ASX:PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today the successful completion of a major upgrade to its proprietary Phylomer libraries of peptides derived from biodiverse bacterial genomes. The improvements achieved with these next generation Phylomer libraries should enable the discovery of higher quality peptide drug candidates with enhanced drug-like characteristics, which could shorten the timelines for lead optimisation.
Initial results show that the new Phylomer libraries are 47-fold larger than the former versions completed in 2009, containing over 126 billion unique peptide sequences in aggregate. These upgraded libraries comprise a broader range of natural biological molecules, capturing more structures from the evolutionary diversity encoded by each respective genome. These libraries are being integrated with a comprehensive upgrade to our discovery platform, incorporating automated processes to enhance the efficiency and scalability of screening.
Phylogica’s Chief Executive Officer Dr Paul Watt commented: “We are committed to technological leadership in the field of peptide drug discovery and our next generation libraries represent a clear advancement in the field. The new libraries are now an integral part of our peptide drug discovery platform and are expected to further enhance the level of interest from prospective Pharma partners. This upgrade is evidence of Phylogica’s continued objective to stay at the forefront of discovery of therapeutic peptides from natural sources.”
For further information please download PDF below:
